Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038474 · ClinicalTrials.gov registry record · Phase 2
Descartes-08 for Patients With Systemic Lupus Erythematosus
A Phase 2 study of Systemic Lupus Erythematosus (SLE), sponsored by Cartesian Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06038474 is a Phase 2 study of Systemic Lupus Erythematosus (SLE) that is active but no longer recruiting, run by Cartesian Therapeutics. The registered enrollment target is 6 participants, below the 1,064-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06038474, a Phase 2 study of Systemic Lupus Erythematosus (SLE), is active but no longer recruiting, sponsored by Cartesian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Conditions Studied
Interventions
- DRUG Descartes-08
Study Locations (1)
California
- Profound Research LLC - Oceanside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06038474
The ClinicalTrials.gov registry entry for NCT06038474 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,064-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (99% lower). The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which Descartes-08 is the first listed.
NCT06038474 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06038474 about?
NCT06038474 is a clinical study titled "Descartes-08 for Patients With Systemic Lupus Erythematosus". This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
What is the current status of trial NCT06038474?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2024-02-12. Estimated completion is 2026-11-01.
What conditions does trial NCT06038474 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).
What interventions are being tested in trial NCT06038474?
The interventions under investigation include: Descartes-08 (DRUG).
Who is sponsoring clinical trial NCT06038474?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038474 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
COMPLETED · Phase 2
-
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
COMPLETED · Phase 2
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.